Post-Transcriptional Control of Type-1 Plasminogen Activator Inhibitor mRNA

  • Joanne H. Heaton
  • Thomas D. Gelehrter
Part of the Endocrine Updates book series (ENDO, volume 16)


In this chapter we will describe the identification of a sequence in the 3’UTR of the type-1 plasminogen activator inhibitor (PAI-1) mRNA that mediates the cyclic nucleotide regulation of mRNA stability. This will be followed by a discussion of the isolation and characterization of a novel RNA-binding protein that interacts with the PAI-1 cyclic nucleotide responsive sequence.


Cyclic Nucleotide High Molecular Weight Complex mRNA Binding Protein Amino Acid Insertion mRNA Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vassalli, J.D., A.P. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J Clin Invest. 88: 1067–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Vassalli, J.D., and M.S. Pepper. 1994. Tumour biology. Membrane proteases in focus. Nature. 370: 14–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Heaton, J.H., and T.D. Gelehrter. 1989. Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. Mol Endocrinol. 3: 349–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Andreasen, P.A., B. Georg, L.R. Lund, A. Riccio, and S.N. Stacey. 1990. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 68: 1–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Heaton, J.H., and T.D. Gelehrter. 1990. Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells. Mol Endocrinol. 4: 171–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Richards, J.S. 2001. New Signaling Pathways for Hormones and Cyclic Adenosine 3’,5’- Monophosphate Action in Endocrine Cells. Mol Endocrinol. 15: 209–218.PubMedCrossRefGoogle Scholar
  7. 7.
    Tian, D., D. Huang, R.C. Brown, and R.A. Jungmann. 1998. Protein kinase A stimulates binding of multiple proteins to a U-rich domain in the 3’-untranslated region of lactate dehydrogenase A mRNA that is required for the regulation of mRNA stability. JBiol Chem. 273: 28454–60.CrossRefGoogle Scholar
  8. 8.
    Nachaliel, N., D. Jain, and Y. Hod. 1993. A cAMP-regulated RNA-binding protein that interacts with phosphoenolpyruvate carboxykinase (GTP) mRNA. J Biol Chem. 268: 24203–9.PubMedGoogle Scholar
  9. 9.
    Themmen, A.P., L.J. Blok, M. Post, W.M. Baarends, J.W. Hoogerbrugge, M. Parmentier, G. Vassart, and J.A. Grootegoed. 1991. Follitropin receptor down-regulation involves a cAMP-dependent post-transcriptional decrease of receptor mRNA expression. Mol Cell Endocrinol. 78: 7–13.CrossRefGoogle Scholar
  10. 10.
    Tholanikunnel, B.G., and C.C. Malbon. 1997. A 20-nucleotide (A + U)-rich element of b2-adrenergic receptor (b2AR) mRNA mediates binding to b2AR-binding protein and is obligate for agonist-induced destabilization of receptor mRNA. J Biol Chem. 272: 11471–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Tholanikunnel, B.G., J.R. Raymond, and C.C. Malbon. 1999. Analysis of the AU-rich elements in the 3’-untranslated region of b2-adrenergic receptor mRNA by mutagenesis and identification of the homologous AU-rich region from different species. Biochemistry. 38: 15564–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang, X., G. Nickenig, and T.J. Murphy. 1997. The vascular smooth muscle type I angiotensin II receptor mRNA is destabilized by cyclic AMP-elevating agents. Mol Pharmacol. 52: 781–7.PubMedGoogle Scholar
  13. 13.
    Lu, D.L., H. Peegel, S.M. Mosier, and K.M. Menon. 1993. Loss of lutropin/human choriogonadotropin receptor messenger ribonucleic acid during ligand-induced down-regulation occurs post transcriptionally. Endocrinology. 132: 235–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Danner, S., M. Frank, and M.J. Lohse. 1998. Agonist regulation of human b2adrenergic receptor mRNA stability occurs via a specific AU-rich element. J Biol Chem. 273: 3223–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang, D., C.J. Hubbard, and R.A. Jungmann. 1995. Lactate dehydrogenase A subunit messenger RNA stability is synergistically regulated via the protein kinase A and C signal transduction pathways. Mol Endocrinol. 9: 994–1004.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee, W.Y., P. Loftin, C.J. Clancey, H. Peng, and J.E. Lever. 2000. Cyclic nucleotide regulation of Na+/glucose cotransporter (SGLT1) mRNA stability. Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3’-untranslated region critical for stabilization. JBiol Chem. 275: 33998–34008.CrossRefGoogle Scholar
  17. 17.
    Kash, J.C., and K.M. Menon. 1999. Sequence-specific binding of a hormonally regulated mRNA binding protein to cytidine-rich sequences in the lutropin receptor open reading frame. Biochemistry. 38: 16889–16897.PubMedCrossRefGoogle Scholar
  18. 18.
    Blaxall, B.C., A.C. Pellett, S.C. Wu, A. Pende, and J.D. Port. 2000. Purification and characterization of beta-adrenergic receptor mRNA-binding proteins. J Biol Chem. 275: 4290–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Fan, X.C., and J.A. Steitz. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17: 3448–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang, W., H. Fumeaux, H. Cheng, M.C. Caldwell, D. Hutter, Y. Liu, N. Holbrook, and M. Gorospe. 2000. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol. 20: 760–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Pinol-Roma, S., and G. Dreyfuss. 1992. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature. 355: 730–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Nargolwalla, C., D. McCabe, and I.B. Fritz. 1990. Modulation of levels of messenger RNA for tissue-type plasminogen activator in rat Sertoli cells, and levels of messenger RNA for plasminogen activator inhibitor in testis peritubular cells. Mol Cell Endocrinol. 70: 73–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Tranque, P., R. Robbins, F. Naftolin, and P. Andrade-Gordon. 1992. Regulation of plasminogen activators and type-I plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes. GLIA. 6: 163–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Fukumoto, S., E.H. Allan, J.A. Yee, T.D. Gelehrter, and T.J. Martin. 1992. Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. JCell Physiol. 152: 346–55.CrossRefGoogle Scholar
  25. 25.
    Thalacker, F.W., and M. Nilsen-Hamilton. 1992. Opposite and independent actions of cyclic AMP and transforming growth factor b in the regulation of type 1 plasminogen activator inhibitor expression. Biochem J. 287: 855–62.PubMedGoogle Scholar
  26. 26.
    Georg, B., A. Riccio, and P. Andreasen. 1990. Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells. Mol Cell Endocrinol. 72: 103–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Konkle, B.A., P.R. Kollros, and M.D. Kelly. 1990. Heparin-binding growth factor-1 modulation of plasminogen activator inhibitor-1 expression. Interaction with cAMP and protein kinase C-mediated pathways. J Biol Chem. 265: 21867–73.PubMedGoogle Scholar
  28. 28.
    DiBattista, J.A., J. Martel-Pelletier, N. Morin, F.C. Jolicoeur, and J.P. Pelletier. 1994. Transcriptional regulation of plasminogen activator inhibitor-1 expression in human synovial fibroblasts by prostaglandin E2: mediation by protein kinase A and role of interleukin-1. Mol Cell Endocrinol. 103: 139–48.PubMedCrossRefGoogle Scholar
  29. 29.
    Heaton, J.H., S. Kathju, and T.D. Gelehrter. 1992. Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. Mol Endocrinol. 6: 53–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Kathju, S. 1994. Regulation of tissue type plasminogen activator gene expression by glucocorticoids and cyclic nucleotides in rat hepatoma cells. Ph.D. Thesis. In Department of Human Genetics. University of Michigan, Ann Arbor.Google Scholar
  31. 31.
    Heaton, J.H., M. Tillmann-Bogush, N.S. Leff, and T.D. Gelehrter. 1998. Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. J Biol Chem. 273: 14261–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Tillmann-Bogush, M., J.H. Heaton, and T.D. Gelehrter. 1999. Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an A-rich sequence. J Biol Chem. 274: 1172–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Chen, C.Y., and A.B. Shyu. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 20: 465–470.PubMedCrossRefGoogle Scholar
  34. 34.
    Kash, J.C., and K.M. Menon. 1998. Identification of a hormonally regulated luteinizing hormone/human chorionic gonadotropin receptor mRNA binding protein. Increased mRNA binding during receptor down-regulation. J Bio! Chem. 273: 10658–10664.CrossRefGoogle Scholar
  35. 35.
    Heaton, J.H., W.M. Dlakic, M. Dlakic, and T.D. Gelehrter. 2001. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide responsive sequence in the type-1 plasminogen activator inhibitor mRNA. J Biol Chem. 276: 3341–3347.PubMedCrossRefGoogle Scholar
  36. 36.
    Ranish, J.A., and S. Hahn. 1991. The yeast general transcription factor TFIIA is composed of two polypeptide subunits. J Biol Chem. 266: 19320–7.PubMedGoogle Scholar
  37. 37.
    Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1996. Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley-Interscience, New York.Google Scholar
  38. 38.
    Loflin, P., C.Y. Chen, and A.B. Shyu. 1999. Unraveling a cytoplasmic role for hnRNP D in the in vivo mRNA destabilization directed by the AU-rich element. Genes Dev. 13: 1884–97.PubMedCrossRefGoogle Scholar
  39. 39.
    Montminy, M. 1997. Transcriptional regulation by cyclic AMP. Annu Rev Biochem. 66: 807–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 89: 5547–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang, Z., and M. Kiledjian. 2000. The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Mol Cell Biol. 20: 6334–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Ford, L.P., J. Watson, J.D, Keene, and J. Wilusz. 1999. ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system. Genes Dev. 13: 188–201.Google Scholar
  43. 43.
    Brewer, G. 1998. Characterization of c-myc 3’ to 5’ mRNA decay activities in an in vitro system. JBiol Chem. 273: 34770–4.CrossRefGoogle Scholar
  44. 44.
    Albright, S.R., and R. Tjian. 2000. TAFs revisited: more data reveal new twists and confirm old ideas. Gene. 242: 1–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Ceman, S., V. Brown, and S.T. Warren. 1999. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol. 19: 7925–32.PubMedGoogle Scholar
  46. 46.
    Wu, X.Q., S. Lefrancois, C.R. Morales, and N.B. Hecht. 1999. Protein-protein interactions between the testis brain RNA-binding protein and the transitional endoplasmic reticulum ATPase, a cytoskeletal g actin and Trax in male germ cells and the brain. Biochemistry. 38: 11261–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Joanne H. Heaton
    • 1
  • Thomas D. Gelehrter
    • 1
  1. 1.University of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations